Skip to content
Review Open access

The osteoarthritis inflammatory ecosystem: a node-edge-boundary-emergent framework toward precision stratification and therapeutic hypothesis generation

Sep 2026 · Frontiers in Medicine · Vol 13 · 0 citations · 115 references
Medicine

Abstract

Osteoarthritis (OA) is a heterogeneous whole-joint disorder in which pain, structural progression and treatment response often diverge from radiographic severity. This mismatch has limited disease-modifying OA drug development and highlights the need for biologically informed patient stratification. Chronic low-grade inflammation contributes to OA progression, but it is embedded within mechanical loading, metabolic dysfunction, synovitis, osteochondral remodeling, cellular senescence and pain sensitization rather than acting as a single-cytokine process. Here, we propose a Node-Edge-Boundary-Emergent (NEBE) inflammatory ecosystem framework that organizes current OA evidence around cellular nodes, communication edges, boundary conditions and emergent disease states. We summarize evidence from human tissue studies, imaging-linked biomarker work, single-cell and spatial analyses, preclinical models and clinical trials. Mechanisms are organized around three translational processes: damage sensing, multicellular network amplification and failed inflammatory resolution. We then discuss candidate biological states, including inflammatory-dominant, metabolic, senescence-associated, osteochondral-remodeling and mechanical-structural OA, and map therapeutic strategies to the ecosystem level they primarily target. Prior failures of cytokine blockade and several disease-modifying approaches may reflect ecosystem mismatch involving the wrong target level, patient population, disease stage or endpoint rather than simple irrelevance of inflammation. Routine phenotyping and MRI may provide first-level stratification, biomarkers may support exploratory trial enrichment and high-cost omics should be reserved for discovery, validation and selected complex cases. Prospective human cohorts and biomarker-guided trials are required to determine whether NEBE-informed stratification improves target engagement, progression prediction or treatment selection beyond existing OA frameworks.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.